Abstract
Immunotoxins(IT) are biologically derived compounds that are under development as anti-neoplastic agents(1`. An immunotoxin consists of a carrier protein that guides a covalently linked toxin to a tumor cell. Monoclonal antibodies which have specificity for tumor cell. Monoclonal antibodies serve as carrier molecules. Plant or bacteria derived toxins such as ricin, pseudomonas exotoxin, and diphtheria toxin are commonly used cellular poisons(2).
To whom requests for reprints should be addressed
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Frankel A, Houston L, Issell, B. Prospects for immunotoxin therapy in cancer.Ann. Rev. Med. 37: 125–142 1986.
Pastan I, Willingham M, Fitzgerald J. Immunotoxins.Cell 47: 641–648 1986.
Olnes S, Sandvig K. How protein toxins enter and kill cells. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 39–74 1988.
Robertus J. D. Toxin structure. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 11–24 1988.
Bjorn M, Ring D, Frankel A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins.Cancer Res. 45: 1214–1221 1985.
Data on file at the Cetus Corporation.
Hertler A, Schlossman D, Borowitz M, Blythnman H, Caselas P, Frankel A. Anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin.Inter. J. of Cancer 43: 215–219.
Blakey D, Thorpe P. Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver. In: Immunotoxins. A. E. Frankel, ed. Kluwer Academic Pub., Norwell, MA 457–474 1988.
Spitler L, del Rio M, Khentigan A, Wedel N, Brophy N, Miller L, Harkonen W, Rosendorf L, Lee H, Mischak R, Kawahata R, Stoudemire J, Fradkin L, Bautista E, Scannon P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibodyricin A chain immunotoxin.Cancer Res. 47: 1717–1723 1987.
Hertler A, Schlossman D, Borowitz M, Laurent G, Jansen F, Schmidt C, Frankel A. A phase I study of T101 ricin A chain immunotoxin in refractory chronic lymphocytic leukemia J. of Biological Response Modifiers 7: 97–113 1988.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gould, B.J., Borowitz, M.J., Groves, E.S., Frankel, A.E. (1989). A Phase I Study of the Anti-Breast Cancer Immunotoxin 260F9 Mab-rRA Given by Intravenous Continuous Infusion. In: Ceriani, R.L. (eds) Breast Cancer Immunodiagnosis and Immunotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1296-4_22
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1296-4_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1298-8
Online ISBN: 978-1-4757-1296-4
eBook Packages: Springer Book Archive